Our results show that despite a reduction in ASCs and circulating IgG2a and IgM during treatment with bortezomib, neither the angiotensin II-induced hypertension or cardiac hypertrophy were attenuated. The gene discussed is AGT; the disease is cardiac hypertrophy.